Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 26 Mar 2015 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 26 Mar 2015 |
| Genmab Acquires Antibody Assets from iDD Biotech | 18 Mar 2015 |
| Genmab Retains Partial Rights for HuMax-TAC-ADC – Will Not Exercise Co-development Right | 16 Mar 2015 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 12 Mar 2015 |